HERIZON-GEA-01: FDA Approval of Zanidatamab + Tislelizumab for HER2+ Esophageai/GEJ/Gastric Adeno

We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody.   We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical practice. Learn about the importance of biomarker testing, the mechanism of action of zanidatamab, and how it compares to traditional therapies like trastuzumab.   Key topics covered in this episode: Overview of the HERIZON-GEA-01 study and its findings Mechanism of action of zanidatamab Comparison of treatment regimens and overall survival benefits Management of side effects, including diarrhea and infusion reactions The role of PD-L1 testing in treatment decisions   Whether you're a healthcare professional or simply interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of treatment for HER2-positive upper GI malignancies.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and check out our other discussions on FDA approvals, treatment algorithms, and challenging cases!   #GastricCancer, #HER2positive, #Zanidatamab, #HERIZONGEA01, #OncologyBrothers